AVAILABLE REAGENTS AND DATA

The Chordoma Foundation seeks to provide easy access to high quality materials needed for research. Below is a partial list of available reagents and data:

Cell lines

- Five validated cell lines are currently available through the Chordoma Foundation’s (CF) special collection at ATCC.
  - Available cell lines: U-CH1, U-CH2, MUG-Chor1, JHC7 and UM-Chor1
  - You can access these cell lines by searching the ATCC website or by visiting https://goo.gl/bFUipe
- CF maintains a repository of cell lines and makes them available to academic and industry investigators at no cost while cell lines are being accessioned at ATCC.
  - Currently, the U-CH11 is available through the CF repository
  - A MTA for this cell line is available at chordoma.org/reagents-data/
- CF makes available whole genome, exome, and RNA sequencing data for all of the cell lines that are deposited at ATCC. Email Patty Cogswell at patty@chordoma.org to request access to this data.

Patient Derived Xenografts (PDX)

- CF maintains a repository of PDX models available to academic and industry investigators at South Texas Accelerated Research Therapeutics (START).
- Currently, the SF8894 PDX model is available for distribution, and a second model, ST087, will be available for distribution shortly. At least two new models should be available by the end of 2016.

Cell Derived Xenografts (CDX)

- Xenografts are being established at START from all validated chordoma cell lines and will be made available upon request.
- The U-CH1 cell line forms tumors that resemble chordomas in NSG mice. A protocol for creating a xenograft using U-CH1 was developed by Dr. Adrienne Flanagan, and is available at chordoma.org/reagents-data/
Genomic Data
Links to publically available genomic data sets are listed at chordoma.org/reagents-data/. These include gene expression microarray, aCGH, whole genome, exome, and transcriptome data.

Tissue
The Chordoma Foundation Biobank collects frozen and FFPE tumor tissue and blood from chordoma patients in the United States. Tissue is obtained with the consent of patients under an IRB approved protocol. Additionally, de-identified tissue samples are contributed to this central repository by five partner hospitals. The Foundation aims to begin accepting requests for tissue samples by the end of 2016.

Tissue Microarrays
TMAs have been established by the following investigators and are available upon request:

- Justin Cates, Vanderbilt University: 10 sacral, 3 spine, 8 skull base
- Raja Seethala, University of Pittsburgh: 79 skull base chordomas and chondrosarcomas
- Adrienne Flanagan, University College London: 41 sacral, 6 lumbar and 3 cervical
- Zhenfeng Duan, Massachusetts General Hospital: 44 sacral and 26 mobile spine
- Florian Grabellus, University Hospital of Essen: 31 skull base, 15 spinal, 14 sacral, and 6 other

Notochord
Notochordal tissue is available from the Congenital Defects Lab at the University of Washington. Contact us for more information.

Drug Screening Pipeline

- The Chordoma Foundation Drug Screening Pipeline offers a centralized drug screening service to rapidly and cost-effectively assess the efficacy of potential new treatments for chordoma in preclinical models of the disease. This service eliminates the need for individual research groups to acquire, establish, and expand mouse models and reduces the time and cost of performing drug screening experiments. Resulting data is shared back with the collaborating investigator or company.
- Contact us or visit our website chordoma.org/research/drug-screening-pipeline/ for more information.

For more information or for assistance obtaining reagents, email manager of research, Patty Cogswell, at patty@chordoma.org.